ad

Top Small-Cap Pharma Stocks Compared: Marksans Pharma vs Caplin Point vs Alembic vs Granules vs Aarti Drugs on Price, Valuation, Q2 FY27 Results and Risks

Previous close: Marksans Pharma Rs 309.20, Caplin Point Rs 2,346.80, Alembic Pharmaceuticals Rs 1,057.10, Granules India Rs 798.95, Aarti Drugs Rs 501.25.


17 Nov 2026 • 10:26 am

Top Small-Cap Pharma Stocks Compared: Marksans Pharma vs Caplin Point vs Alembic vs Granules vs Aarti Drugs on Price, Valuation, Q2 FY27 Results and Risks

Quick Answer

This small-cap pharma stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Marksans Pharma, Caplin Point, Alembic Pharmaceuticals, Granules India and Aarti Drugs. Granules India is the largest by market capitalisation at Rs 22,937 crore. Caplin Point reports the highest return on equity at 17.88%. Small-cap pharma companies differ in exports, APIs and branded sales, so read each multiple next to margins and returns.

Small-cap pharma stocks compared here means Marksans Pharma, Caplin Point, Alembic Pharmaceuticals, Granules India and Aarti Drugs on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group covers a formulations exporter, a Latin America focused maker, a branded and generic maker, an API and formulations producer and an intermediates maker, so each name earns from a different corner of pharma, which is exactly why a side-by-side look helps.

All five companies have filed their September 2026 quarter, so every result below is Q2 FY27. Small-cap pharma stocks follow export approvals, launches and raw material costs, so a glance at the Nifty Pharma page and the Sensex page before you read the tables gives useful backdrop.

Click Here – Get Free Investment Predictions

Small-Cap Pharma Stocks Compared: Five Names on the List

The small-cap pharma stocks compared here are Marksans Pharma, Caplin Point, Alembic Pharmaceuticals, Granules India and Aarti Drugs. Granules India is the largest by market capitalisation at Rs 22,937 crore. Previous closes run from Rs 309.20 for Marksans Pharma to Rs 2,346.80 for Caplin Point, which is why a side-by-side look at value rather than price is more useful. This small-cap pharma stocks compared list is the base for every table that follows.

Stock Previous close (Rs) Market cap (Rs crore)
Marksans Pharma 309.20 14,471
Caplin Point 2,346.80 18,155
Alembic Pharmaceuticals 1,057.10 20,576
Granules India 798.95 22,937
Aarti Drugs 501.25 4,566

A quick look at the business behind each ticker puts the numbers in context. Marksans Pharma makes formulations for developed markets, while Caplin Point makes and sells pharma products in Latin America and Africa. Alembic Pharmaceuticals makes branded and generic medicines, and Granules India makes APIs and finished dosages. To compare small-cap pharma stocks properly, line up price to earnings, return on equity and operating margin before forming a view.

Rounding out the group, Aarti Drugs makes APIs and intermediates. A fair small-cap pharma stock comparison looks at what each company actually earns from, not only at the share price. A formulations exporter and an API maker belong in separate mental boxes whenever you compare small-cap pharma stocks fairly.

Small-Cap Pharma Stocks Valuation: Multiples, Returns and Payouts

Aarti Drugs trades at the lowest price to earnings ratio in this group at 19.96. Caplin Point reports the highest return on equity at 17.88%. Aarti Drugs has the lowest price to book value at 2.72. These small-cap pharma stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this small-cap pharma stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.

Stock Price to earnings Price to book ROE (%) Dividend yield (%) Debt to equity
Marksans Pharma 25.58 4.34 16.80 0.28 0.14
Caplin Point 25.93 4.65 17.88 0.33 0.00
Alembic Pharmaceuticals 24.50 3.46 14.20 1.15 0.26
Granules India 32.14 3.49 10.87 0.19 0.17
Aarti Drugs 19.96 2.72 13.61 0.40 0.37

Price to earnings, return on equity and debt to equity show valuation and balance sheet room, while dividend yield shows payouts at the cash rich names. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple small-cap pharma stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.

In this group, price to earnings runs from 19.96 for Aarti Drugs to 32.14 for Granules India. Alembic Pharmaceuticals offers the highest dividend yield at 1.15%. Industry price to earnings readings differ by sub-sector: Marksans Pharma, Caplin Point, Alembic Pharmaceuticals and Granules India at 40.55; Aarti Drugs at 40.13. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built small-cap pharma stock comparison also notes that product launches and approvals can move margins between quarters. Run the same small-cap pharma stock comparison on your own watchlist and the pattern in these numbers will be easier to spot.

Small-Cap Pharma Stocks Q2 FY27 Results: Revenue and Profit Check

All of the five small-cap pharma stocks compared have filed Q2 FY27 numbers. Alembic Pharmaceuticals posted the fastest revenue growth at 36.6% year on year. Aarti Drugs showed the sharpest rise in net profit at 83.3%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this small-cap pharma stocks compared review as a snapshot of one quarter, not a verdict on any pharma company.

Stock Q2 FY27 revenue (Rs crore) Q2 FY26 revenue (Rs crore) Q2 FY27 net profit (Rs crore) Q2 FY26 net profit (Rs crore)
Marksans Pharma 958.3 742.0 143.5 99.1
Caplin Point 663.1 564.4 182.3 160.2
Alembic Pharmaceuticals 2,619 1,917 333.9 183.7
Granules India 1,571 1,296 181.8 130.6
Aarti Drugs 828.8 652.9 82.8 45.2

Marksans Pharma Results Snapshot

Marksans Pharma reported Q2 FY27 revenue of Rs 958.3 crore, compared with Rs 742.0 crore a year earlier, a rise of 29.2%. Net profit rose 44.8% to Rs 143.5 crore from Rs 99.1 crore. Operating margin expanded to 24.7% from 23.1% a year ago. Earnings per share for the quarter rose to Rs 3.11 from Rs 2.17.

Caplin Point Results Snapshot

In the September 2026 quarter, Caplin Point booked revenue of Rs 663.1 crore against Rs 564.4 crore in the same quarter last year, a rise of 17.5%. Net profit rose 13.8% to Rs 182.3 crore from Rs 160.2 crore. Earnings per share for the quarter rose to Rs 23.37 from Rs 20.25.

Alembic Pharmaceuticals Results Snapshot

Alembic Pharmaceuticals' Q2 FY27 top line stood at Rs 2,619 crore, versus Rs 1,917 crore in Q2 FY26, a rise of 36.6%. Net profit rose 81.8% to Rs 333.9 crore from Rs 183.7 crore. Operating margin expanded to 22.2% from 17.0% a year ago. Earnings per share for the quarter rose to Rs 17.05 from Rs 9.40.

Granules India Results Snapshot

Granules India reported Q2 FY27 revenue of Rs 1,571 crore, compared with Rs 1,296 crore a year earlier, a rise of 21.2%. Net profit rose 39.2% to Rs 181.8 crore from Rs 130.6 crore. Operating margin expanded to 22.6% from 21.4% a year ago. Earnings per share for the quarter rose to Rs 7.03 from Rs 5.38.

Aarti Drugs Results Snapshot

In the September 2026 quarter, Aarti Drugs booked revenue of Rs 828.8 crore against Rs 652.9 crore in the same quarter last year, a rise of 26.9%. Net profit rose 83.3% to Rs 82.8 crore from Rs 45.2 crore. Operating margin expanded to 16.7% from 12.9% a year ago. Earnings per share for the quarter rose to Rs 9.07 from Rs 4.95.

Product launches, plant approvals and raw material costs set earnings, so margins can move between quarters, so profit can look different from revenue in a single quarter. That is why a small-cap pharma stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a small-cap pharma stocks compared review becomes a map of the sector rather than a price list. When you compare small-cap pharma stocks after each result season, track how operating margin changes from one quarter to the next. A small-cap pharma stock comparison built on one quarter of data is a starting point, and the next set of results will update it.

Small-Cap Pharma Stocks Compared Two at a Time: Three Pairings

Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare small-cap pharma stocks two at a time.

Marksans Pharma vs Caplin Point

Marksans exports formulations to developed markets, while Caplin Point focuses on Latin America and Africa. Caplin Point is about 1.3 times the size of Marksans Pharma by market capitalisation, at Rs 18,155 crore against Rs 14,471 crore. On price to earnings, Marksans Pharma carries the lower multiple at 25.58 against 25.93 for Caplin Point. Caplin Point reports the higher return on equity, at 17.88% against 16.80% for Marksans Pharma. Two export focused companies serve different regions, so read geography next to valuation.

Granules India vs Aarti Drugs

Granules makes APIs and finished dosages, while Aarti Drugs makes APIs and intermediates. On price to earnings, Aarti Drugs carries the lower multiple at 19.96 against 32.14 for Granules India. Aarti Drugs reports the higher return on equity, at 13.61% against 10.87% for Granules India. For dividend income, Aarti Drugs offers 0.40% against 0.19% at Granules India. Both sit upstream of finished drugs, so compare margins carefully.

Alembic Pharmaceuticals vs Marksans Pharma

Alembic sells branded and generic products in India and abroad, while Marksans leans on exports. Marksans Pharma reports the higher return on equity, at 16.80% against 14.20% for Alembic Pharmaceuticals. For dividend income, Alembic Pharmaceuticals offers 1.15% against 0.28% at Marksans Pharma. In Q2 FY27, Alembic Pharmaceuticals grew revenue faster, at 36.6% year on year against 29.2% for Marksans Pharma. A mixed domestic and export model and an export model respond to different triggers.

Best Small-Cap Pharma Stocks for Each Type of Investor

Searching for the best small-cap pharma stocks usually means different things to different readers. The table below shows who leads on each measure today, so you can pick the row that matches your goal. Any small-cap pharma stocks compared table can mislead if you stop at one row, because each pharma company leads on a different measure.

If you care most about Start your research with The number
Lowest price to earnings Aarti Drugs 19.96
Highest return on equity Caplin Point 17.88%
Highest dividend yield Alembic Pharmaceuticals 1.15%
Lowest price to book value Aarti Drugs 2.72
Largest by market capitalisation Granules India Rs 22,937 crore
Fastest Q2 FY27 revenue growth Alembic Pharmaceuticals 36.6%
Sharpest Q2 FY27 net profit rise Aarti Drugs 83.3%

No single name tops every row, which is exactly why a small-cap pharma stock comparison helps. Margins, returns and valuation point to different companies, so decide what matters most to you before you rank the numbers.

What Is Driving Small-Cap Pharma Companies Right Now?

Export approvals, generic launches and steady domestic demand support smaller pharma companies. Knowing what moves product launches and plant approvals helps you compare small-cap pharma stocks with the right questions in mind.

Product mix, plant approvals and input costs decide earnings, so companies with a broad product base can show steadier numbers. A good small-cap pharma stocks compared routine therefore tracks product launches, plant approvals and export demand.

Risks to Weigh When You Compare Small-Cap Pharma Stocks

Small-Cap Pharma stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Every small-cap pharma stock comparison has blind spots, and for this group the biggest is product launches and plant approvals.

Because product launches, plant approvals and export demand drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this small-cap pharma stocks compared guide a balanced starting point.

How to Compare Small-Cap Pharma Stocks and Build a Shortlist

Start by deciding whether you want an exporter, a regional specialist, an API maker or a branded and generic mix, because each responds to different triggers. Readers who track plant approvals find the group easier to follow. Done step by step, this small-cap pharma stocks compared routine becomes repeatable rather than a one-off exercise.

Then check valuation and returns, because smaller pharma names can carry wide multiple gaps. An exporter next to an API maker shows how business models change the numbers. Keep the shortlist of best small-cap pharma stocks short enough that you can actually follow each company's quarterly results. When you compare small-cap pharma stocks again after new results, update only the rows that changed instead of starting over.

The Univest stock screener lets you filter small-cap pharma stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this small-cap pharma stocks compared page after the next set of results to see which numbers have moved.

Check the Univest Screener for live small-cap pharma stock data

Download the Univest iOS App or Univest Android App to track these small-cap pharma stocks live.

Conclusion: Small-Cap Pharma Stocks Compared at a Glance

This small-cap pharma stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Granules India leads on size and Caplin Point leads on return on equity, while the others bring their own strengths. Treat the small-cap pharma stocks Q2 FY27 results and small-cap pharma stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare small-cap pharma stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Small-Cap Pharma Stocks Compared

Which are the top small-cap pharma stocks compared in this article?

Ans. The small-cap pharma stocks compared in this article are Marksans Pharma, Caplin Point, Alembic Pharmaceuticals, Granules India and Aarti Drugs. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, which gives you one tidy table to work from before you read any filing in detail.

Which small-cap pharma stock has the highest market capitalisation?

Ans. Among the five names, Granules India has the highest market capitalisation at Rs 22,937 crore. Alembic Pharmaceuticals follows at Rs 20,576 crore. Because market capitalisation is simply share price multiplied by shares outstanding, it shifts daily, so confirm the live number before using it.

Which of these small-cap pharma stocks has the lowest price to earnings ratio?

Ans. On small-cap pharma stocks valuation, Aarti Drugs has the lowest price to earnings ratio among these small-cap pharma stocks at 19.96, based on the latest reported earnings. Granules India sits at the other end at 32.14. A low multiple can reflect slower growth or higher risk as easily as a bargain, so read it next to growth and margins.

Which small-cap pharma stock has the highest return on equity?

Ans. Caplin Point reports the highest return on equity in this group at 17.88%. The ratio measures profit earned for every rupee of shareholder money, which makes it a quick test of capital efficiency. One year can mislead, so look at several, and remember that borrowing can push the figure up.

How did small-cap pharma stocks perform in Q2 FY27 results?

Ans. All of the five names have filed Q2 FY27 numbers in our data. Alembic Pharmaceuticals recorded the fastest revenue growth at 36.6% year on year. Aarti Drugs showed the sharpest net profit rise at 83.3%. For small-cap pharma stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.

What are the main risks when you compare small-cap pharma stocks?

Ans. Small-Cap Pharma stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on product launches, plant approvals and export demand.

Which metrics matter most when you compare small-cap pharma stocks?

Ans. Revenue growth, operating margin, return on equity and debt to equity show operating strength and balance sheet room. Price to earnings shows how the market values each company. Read each filing for approval and product commentary.

Which is the best small-cap pharma stock to buy among these five?

Ans. The best small-cap pharma stock depends on whether you want an exporter, a regional specialist, an API maker or a branded mix, because the five names differ on all of these. On the numbers in this article, Granules India has the largest market capitalisation; Aarti Drugs has the lowest price to earnings; Caplin Point has the highest return on equity; Alembic Pharmaceuticals has the highest dividend yield. Each name wins on a different row, and this is educational content rather than advice. Build a shortlist from the tables, read the latest filings, and talk to a SEBI-registered advisor, because your own goals and risk appetite decide the right fit.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down